Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Hum Gene Ther. 2018 Dec;29(12):1438-1448. doi: 10.1089/hum.2017.256. Epub 2018 Sep 5.
Long noncoding RNAs (lncRNAs) are important regulators in various human diseases. The lncRNA is a tumor promoter in ovarian cancer, glioma, and lung cancer, but the specific effects of on cervical cancer (CC) chemoresistance remain unclear. Here, the level of HOXD-AS1 in nonmalignant and CC tissues as well as in CC cells and cisplatin-resistant CC cells was determined. qRT-PCR indicated that was overexpressed in CC tissues and cisplatin-resistant CC cells. Loss-of-function assays showed that downregulation of expression suppressed chemoresistance of cisplatin-resistant CC cells. targeted , and in gain-of-function assays could reverse cisplatin resistance of CC cells. in turn targeted zinc finger E-box homeobox 1 (). These results collectively show that HOXD-AS1 can act as a competing endogenous RNA to upregulate expression via . The effects of the axis on cisplatin resistance of cisplatin-resistant CC cells were supported by rescue assay results. In summary, enhanced chemoresistance of cisplatin-resistant CC cells by modulating axis expression.
长链非编码 RNA（lncRNA）是多种人类疾病中的重要调控因子。在卵巢癌、神经胶质瘤和肺癌中，lncRNA 是一种肿瘤促进因子，但它在宫颈癌（CC）化疗耐药中的具体作用尚不清楚。本研究旨在检测非恶性和 CC 组织以及 CC 细胞和顺铂耐药 CC 细胞中 HOXD-AS1 的水平。qRT-PCR 结果表明，HOXD-AS1 在 CC 组织和顺铂耐药 CC 细胞中表达上调。功能丧失实验表明，下调 HOXD-AS1 表达可抑制顺铂耐药 CC 细胞的化疗耐药性。HOXD-AS1 可作为竞争性内源性 RNA 通过 靶向 ，并在功能获得实验中可逆转 CC 细胞的顺铂耐药性。 反过来又靶向锌指 E 盒同源盒 1（）。这些结果共同表明，HOXD-AS1 通过 轴上调 表达来增强顺铂耐药 CC 细胞的化疗耐药性。挽救实验结果支持 轴对顺铂耐药 CC 细胞化疗耐药性的影响。综上所述，通过调节 轴表达， 增强了顺铂耐药 CC 细胞的化疗耐药性。
